TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18635500
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg tramadol (group T)
Study: 12392384
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 250 microg administered once daily
Study: 8611112
Drug: Active loperamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active loperamide suppositories (20 mg b.d. x 1 week)
Study: 2167791
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of atrial natriuretic factor at doses of 0.5, 2 and 10 pmol min‐1 kg‐1
Study: 2167791
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of atrial natriuretic factor at a pharmacological dose of 50 pmol min‐1 kg‐1
Study: 6944146
Drug: Viral oncolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viral oncolysate (formalin-treated fowl plaque virus-infected allogenous leukemia cells) in addition to maintenance chemotherapy
Study: 21593672
Drug: i-gel (novices)
Normalized name: IOBENGUANE I 123
Approvals — FDA: no, EMA: no, PMDA: no
Description: i-gel (novices)
Study: 21593672
Drug: i-gel (experienced)
Normalized name: IOBENGUANE I 123
Approvals — FDA: no, EMA: no, PMDA: no
Description: i-gel (experienced)
Study: 17683540
Drug: Coxibs (cyclooxygenase-2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coxibs (cyclooxygenase-2 selective inhibitors)
Study: 10410789
Drug: lodoxamide tromethamine
Normalized name: Lodoxamide Tromethamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: lodoxamide tromethamine 0.1% ophthalmic solution
Study: 31860383
Drug: Refrigerated formulation
Normalized name: Refrigerant 114
Approvals — FDA: no, EMA: no, PMDA: no
Description: Refrigerated formulation (RF) of VGX-3100
Study: 31860383
Drug: Frozen formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frozen formulation (FF) of VGX-3100
Study: 26134388
Drug: Flaxseed mucilage
Normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed mucilage (10 g)
Study: 26134388
Drug: L. paracasei
Normalized name: L. paracasei/L. rhamnosus 11 billion cell ORAL CAPSULE
DrugBank: Lactobacillus paracasei (DB16551)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L. paracasei F19 (9.4 × 10^10 colony-forming units)
Study: 7547041
Drug: Lower limb
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower limb IVRA with 0.1 mg of HIDA labelled with 100 muCi of 99mTc in 40 ml of saline; tourniquet inflated for 20 min.
Study: 7547041
Drug: Upper limb
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Upper limb IVRA with 0.1 mg of HIDA labelled with 100 muCi of 99mTc in 40 ml of saline; tourniquet inflated for 20 min.
Study: 6122738
Drug: Ranitidine hydrochloride
Normalized name: Ranitidine Hydrochloride
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine hydrochloride 200mg twice daily for six weeks
Study: 6122738
Drug: Ranitidine hydrochloride
Normalized name: Ranitidine Hydrochloride
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine hydrochloride 100mg at night for one year as maintenance treatment
Study: 28475678
Drug: Creatine (20 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine (20 g/day load×5 days followed by 2 g/day orally)
Study: 18000538
Drug: SP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SP plus azithromycin (1 g/day x 2 days)
Study: 18000538
Drug: SP plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: SP plus artesunate (200 mg/day x 3 days)
Study: 18000538
Drug: sulfadoxine-pyrimethamine (SP;
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulfadoxine-pyrimethamine (SP; 3 tablets, 500 mg sulfadoxine and 25 mg pyrimethamine per tablet)
Study: 8043996
Drug: Ligustrazine 160
Normalized name: LIGUSTRAZINE
DrugBank: Ligustrazine (DB19074)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ligustrazine 160 mg intravenously for 10 days
Study: 31898939
Drug: Reduced-dose tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reduced-dose tacrolimus with standard-dose mycophenolate mofetil (MMF)
Study: 31898939
Drug: Standard-dose tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard-dose tacrolimus with reduced-dose mycophenolate mofetil (MMF)
Study: 27151255
Drug: Eltrombopag (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag (up to 75 mg/day) for 7 or 13 weeks
Study: 27151255
Drug: Eltrombopag (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag (up to 75 mg/day)
Study: 27151255
Drug: Eltrombopag (open-label
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag (open-label treatment for ≥24 weeks)
Study: 21079428
Drug: Isoniazid preventive
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid preventive therapy (IPT) with HAART
Study: 18434189
Drug: Escitalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (20 mg/day) + Naltrexone (50 mg/day)
Study: 18434189
Drug: Escitalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (20 mg/day) + GHB (75 mg/kg)
Study: 18434189
Drug: Escitalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (20 mg/day) + Naltrexone (50 mg/day) + GHB (75 mg/kg)
Study: 12660585
Drug: 1% carteolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% carteolol alginate once daily
Study: 12660585
Drug: 1% carteolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% carteolol standard solution twice daily
Study: 8097273
Drug: Fluconazole (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (150 mg oral dose, once a week)
Study: 3513516
Drug: Instant and
Normalized name: Advanced Eye Relief Redness Instant Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instant and sustained-release verapamil
Study: 3513516
Drug: Verapamil (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (all formulations)
Study: 28074135
Drug: Aclidinium 400
Normalized name: aclidinium 400 mcg/inh inhalation powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aclidinium 400 µg twice daily
Study: 22142458
Drug: 100 ml
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml vodka (30 g alcohol) with 200 ml orange juice
Study: 16103605
Drug: Praziquantel (offered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (offered to individuals uncured after two myrrh treatments)
Study: 11941903
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment in women
Study: 11941903
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment in men
Study: 11941903
Drug: One drug
Normalized name: mometasone Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drug treatment
Study: 11941903
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination therapy
Study: 11941903
Drug: Free combination
Normalized name: SUNSCREEN-29 PABA-FREE COMBINATION LOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free combination therapy
Study: 11941903
Drug: ACE inhibitors/AT‐II
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors/AT‐II antagonists
Study: 10024093
Drug: Resistant starch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistant starch supplements
Study: 8636524
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of liquid 5% lidocaine
Study: 8636524
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of 2% lidocaine paste
Study: 2149050
Drug: Vancomycin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (30 mg/kg/d)
Study: 2149050
Drug: Teicoplanin (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin (6 mg/kg every 12 h on day 1, then daily)
Study: 398661
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg domperidone I.V.
Study: 398661
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg domperidone I.V.
Study: 31923565
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g kg‐1 Fishwort Powder (FWP)
Study: 31094461
Drug: Umifenovir (Arbidol)
Normalized name: umifenovir
DrugBank: Umifenovir (DB13609)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Umifenovir (Arbidol) 800 mg/day for 5 days (n=181)
Study: 26118077
Drug: Homotoxicological medicines
Normalized name: Percy Medicine
DrugBank: Bismuth subsalicylate (DB01294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Homotoxicological medicines (Lymphomyosot, Galium‐Heel®, Traumeel S, Echinacea compositum S, Bronchalis‐Heel®, Mucosa compositum) in addition to standard anti‐inflammatory therapy
Study: 26118077
Drug: Standard anti‐inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard anti‐inflammatory therapy
Study: 21996132
Drug: Dexfenfluramine 40
Normalized name: dexfenfluramine
DrugBank: Dexfenfluramine (DB01191)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexfenfluramine 40 mg (n = 6)
Study: 21996132
Drug: Dexfenfluramine 60
Normalized name: dexfenfluramine
DrugBank: Dexfenfluramine (DB01191)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexfenfluramine 60 mg (n = 7)
Study: 21996132
Drug: Dexfenfluramine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexfenfluramine (both doses)
Study: 17719273
Drug: Maximal in-hospital
Normalized name: Spirulina maxima preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maximal in-hospital diuretic dose
Study: 15808387
Drug: Oxybutynin starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin starting dose of 2.5 mg bd
Study: 15808387
Drug: Oxybutynin starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin starting dose of 5 mg nocte
Study: 9448164
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg once daily, amoxicillin 500 mg t.i.d., metronidazole 500 mg t.i.d.
Study: 9448164
Drug: Amoxicillin 500
Normalized name: amoxicillin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 500 mg t.i.d., metronidazole 500 mg t.i.d.
Study: 2121360
Drug: Selegiline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline (10 mg tablets once daily)
Study: 2121360
Drug: Phosphatidylserine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphatidylserine (100 mg capsules twice daily)
Study: 20035984
Drug: 200 U
Normalized name: lipase 1200 UNT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 U BTX‐A initially, with subsequent injections between 100 and 300 U
Study: 20035984
Drug: Dose alteration
Normalized name: SLICK ALTERATION DISRUPTING BOS TAURUS G.(NC_037347.1) FS(39099129-39099368) IN EXON 9 OF PRLR GENE IN BOS TAURUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose alteration in BTX‐A
Study: 20035984
Drug: Repeated injections
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated injections of BTX‐A
Study: 15758796
Drug: Tolterodine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolterodine (2 mg daily)
Study: 10966890
Drug: Lipid emulsion
Normalized name: propofol lipid emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid emulsion (10% triacylglycerol emulsion) + heparin (200 U bolus followed by 0.2 U*min(‐)(1)*kg body wt(‐)(1)) for 180 min
Study: 10966890
Drug: Lipid emulsion
Normalized name: propofol lipid emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid emulsion + heparin with propranolol infusion (n = 8)
Study: 8828369
Drug: Aprotinin high-dose
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprotinin high-dose (300 x 10^4 units)
Study: 8828369
Drug: Aprotinin low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Aprotinin low-dose (100 x 10^4 units)
Study: 1325880
Drug: Enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 10 mg/day for 3 weeks and then 20 mg/day for 4 weeks (n = 12)
Study: 1325880
Drug: Doxazosin 1-8
Normalized name: doxazosin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin 1-8 mg/day
Study: 1325880
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with doxazosin and enalapril
Study: 30851536
Drug: Premature Infant
Normalized name: Premature infant formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premature Infant Oral Motor Intervention (PIOMI) administered over 10 days.
Study: 29214740
Drug: Intravitreal dexamethasone
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal dexamethasone (400 μg) plus intravitreal antibiotics (0.2 mg vancomycin and 0.05 mg gentamicin)
Study: 29214740
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus intravitreal antibiotics (0.2 mg vancomycin and 0.05 mg gentamicin)
Study: 29214740
Drug: Intravitreal dexamethasone
Normalized name: Dexamethasone Intravitreal Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal dexamethasone (400 μg) plus intravitreal antibiotics
Study: 29214740
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus intravitreal antibiotics
Study: 26768146
Drug: Drug Eluting
Normalized name: Drug eluting stent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Eluting Balloon (DCB)
Study: 27041697
Drug: Presurgical orthodontic
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presurgical orthodontic treatment before secondary alveolar bone grafting (SABG)
Study: 27041697
Drug: Conventional SABG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional SABG alone (without presurgical orthodontic treatment)
Study: 20405117
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 80 ppm inhaled nitric oxide (iNO) and 100% oxygen (O(2))
Study: 18315511
Drug: Scalp acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scalp acupuncture (scalp AP) sessions twice weekly for 9 months in group B, alongside language therapy (LT).
Study: 18315511
Drug: Language therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Language therapy (LT) twice weekly for 9 months in both groups.
Study: 12423324
Drug: Melatonin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (5 mg in the evening)
Study: 10066203
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose rivastigmine (6-12 mg/day)
Study: 10066203
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose rivastigmine (1-4 mg/day)
Study: 1914054
Drug: Low-dose alfentanil
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose alfentanil (35.1 micrograms.kg‐1 then continuous infusion of 16.2 micrograms.kg‐1.hr‐1)
Study: 1914054
Drug: Mid-dose alfentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mid-dose alfentanil (70.2 micrograms.kg‐1 then continuous infusion of 32.4 micrograms.kg‐1.hr‐1)
Study: 1914054
Drug: High-dose alfentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose alfentanil (105.3 micrograms.kg‐1 then continuous infusion of 48.6 micrograms.kg‐1.hr‐1)
Study: 1914054
Drug: Fentanyl (8.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (8.3 micrograms.kg‐1 then continuous infusion of 1.6 micrograms.kg‐1.hr‐1)
Study: 6307933
Drug: Pectin (36
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pectin (36 g/d for 3 weeks)
Study: 29298102
Drug: Deer Bone
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deer Bone Extract (DBE) 550 mg/day for 12 weeks
Study: 26792619
Drug: Aquatic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aquatic therapy (pool exercises) starting 6 days after surgery
Study: 26792619
Drug: Timing of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Timing of aquatic therapy
Study: 21841518
Drug: Combination paste
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination paste (morphine + methylprednisolone)
Study: 21841518
Drug: Steroid paste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid paste (methylprednisolone alone)
Study: 21841518
Drug: Morphine paste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine paste (morphine alone)
Study: 12081672
Drug: Traditional injection
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional injection technique
Study: 10638393
Drug: Intravenous N-acetylcysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous N-acetylcysteine infusion (3.4-4.6 mg/kg/h for 24 hours in study I; 0.3-1.3 mg/kg/h for 6 days in study II)
Study: 7022295
Drug: Low-dose CMF
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose CMF (cyclophosphamide, methotrexate, and 5-fluorouracil)
Study: 7022295
Drug: Standard-dose CMF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose CMF (cyclophosphamide, methotrexate, and 5-fluorouracil)
Study: 23211271
Drug: Joint reminiscence
Normalized name: ActivOn Joint & Muscle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Joint reminiscence groups held weekly for 12 consecutive weeks, followed by monthly maintenance sessions for a further 7 months.
Study: 15834098
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg oral moxifloxacin (two doses with a 12 hour interval)
Study: 10566928
Drug: Laryngeal mask
Normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Laryngeal mask airway (LMA) with cuff volumes ranging from 0 to 40 ml
Study: 10566928
Drug: Cuffed oropharyngeal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cuffed oropharyngeal airway (COPA) with cuff volumes ranging from 0 to 60 ml
Study: 27502803
Drug: Kinesio Taping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinesio Taping (KT) in addition to neurodevelopmental therapy (NDT)
Study: 27502803
Drug: Neuromuscular electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neuromuscular electrical stimulation (NMES) in addition to neurodevelopmental therapy (NDT)
Study: 24821594
Drug: Pyrazinamide MIC
Normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyrazinamide MIC ≤ 50 mg/L
Study: 24821594
Drug: Pyrazinamide MIC
Normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyrazinamide MIC > 50 mg/L
Study: 24821594
Drug: Standard combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard combination therapy (isoniazid, rifampicin, pyrazinamide, ethambutol)
Study: 20692169
Drug: Anti-tuberculosis treatment
Normalized name: Mycobacterium tuberculosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-tuberculosis treatment (ATT)
Study: 20692169
Drug: Current standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current standard therapies (Control)
Study: 17464305
Drug: 360 degrees
Normalized name: NEEDLE 20G 1IN BENT 90 DEGREES
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360 degrees total capsule cover (group I)
Study: 17464305
Drug: Quartile change
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quartile change in area of capsule cover
Study: 15849647
Drug: Sports medicine
Normalized name: Mueller Sports Medicine Compression Glove
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sports medicine class
Study: 15849647
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (students not participating in the sports medicine class)
Study: 9708514
Drug: 1 mCi/4
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mCi/4 ml unfiltered 99mTc‐sulfur colloid injected in four divided doses around the palpable lesion or adjacent to the excision cavity
Study: 26563923
Drug: Multimodal analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal analgesic (MMA) injection with morphine, ropivacaine, and methylprednisolone
Study: 23510018
Drug: Switch to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Switch to the highest approved dose of rosuvastatin (40 mg)
Study: 23510018
Drug: Add-on extended
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on extended release nicotinic acid (ER-NA)/l-aropiprant (LRPT)
Study: 20706728
Drug: Flaxseed oil
Normalized name: Flaxseed Oil
DrugBank: Linseed oil (DB11357)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed oil capsules (11 g/day)
Study: 20706728
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil capsules (2 g/day + 9 g/day of olive oil)
Study: 20706728
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil capsules (11 g/day)
Study: 19936516
Drug: 10% Lippia
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% Lippia Sidoides (LS) gel
Study: 25523604
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel (control group)
Study: 11299133
Drug: Sertraline 100mg
Normalized name: sertraline 100 MG
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline 100mg per day for 2 weeks
Study: 9882034
Drug: Empirical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical treatment with omeprazole
Study: 9882034
Drug: Prompt endoscopy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prompt endoscopy followed by directed medical treatment
Study: 2803882
Drug: Bupivacaine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine with fentanyl (loading dose of 0.5% bupivacaine 6.0 ml and fentanyl 100 micrograms, followed by infusion of 0.08% bupivacaine 15 ml h‐1 plus fentanyl 37.5 micrograms h‐1)
Study: 2803882
Drug: Bupivacaine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine alone (loading dose of 0.5% bupivacaine 6.0 ml and saline 2.0 ml, followed by infusion of 0.08% bupivacaine alone)
Study: 4827462
Drug: 2.5 mg/70
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/70 kg heroin
Study: 4827462
Drug: 5 mg/70
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/70 kg heroin
Study: 31620896
Drug: HPP/target therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPP/target therapy